Related Experiment Videos
Screening for CMV retinitis using chromatic discrimination thresholds and achromatic contrast sensitivity
R S Newsom1, G L Ong, T L Jackson
1Sussex Eye Hospital, Brighton. rbnewsom@dircon.co.uk
The British Journal of Ophthalmology
|July 25, 2000
Summary
Cytomegalovirus retinitis (CMVR) screening in HIV+ patients can be improved. Chromatic discrimination and achromatic contrast sensitivity tests effectively detect CMVR, aiding early diagnosis in vulnerable populations.
Area of Science:
- Ophthalmology
- Virology
- Immunology
Background:
- Cytomegalovirus retinitis (CMVR) often presents asymptomatically in HIV+ patients with low CD4 counts.
- Effective screening tests for early CMVR detection are crucial for timely intervention.
- Current retinal function tests have limited efficacy in identifying CMVR.
Purpose of the Study:
- To evaluate chromatic discrimination thresholds and achromatic contrast sensitivity as potential screening tools for CMVR in HIV+ individuals.
- To compare the visual function of HIV+ patients with CMVR to HIV+ patients without CMVR and healthy controls.
Main Methods:
- Recruited 11 HIV+ patients with CMVR, 16 HIV+ patients without CMVR, and 29 age-matched controls.
- Measured visual acuity, chromatic discrimination thresholds, and achromatic contrast sensitivity.
- Performed fundal examination via slit lamp biomicroscopy and graded CMVR from photographs.
Main Results:
- Patients with CMVR showed significant loss in tritan (p<0.0005) and red/green (p<0.05) chromatic discrimination.
- Achromatic contrast sensitivity was reduced in CMVR patients at spatial frequencies of 2.2, 3.4, and 10 cpd (p<0.05).
- No significant differences were observed between HIV+ patients and controls for any tested visual function (p>0.1).
Conclusions:
- HIV+ patients diagnosed with CMVR exhibit impaired chromatic discrimination and achromatic contrast sensitivity.
- These visual function deficits suggest that chromatic and achromatic tests can serve as effective screening methods for CMVR in HIV+ individuals.